Buy 6-APB Drug Online, 6-(2-Aminopropyl)benzofuran (also known as 6-APB and “Benzofury“) is a novel entactogen substance of the benzofuran class. Its characteristic effects include anxiety suppression, disinhibition, muscle relaxation, and euphoria. It is structurally related to entactogens like MDA, MDMA, 5-APB, and 5-MAPB.
6-APB was first synthesized in 1993 by David E. Nichols as a potential non-neurotoxic alternative to MDMA. However, it did not come into popular recreational use until over a decade later, where it briefly entered the rave scene and global research chemicals market. It was sold along with other novel benzofuran entactogens under the name “Benzofury” before its sale and import were subsequently banned.
Buy 6-APB Drug Online
Very little data exists about the pharmacological properties, metabolism, and toxicity of 6-APB, and it has only a brief history of human usage. It has been marketed alongside research chemical entactogens like 5-MAPB and 5-APB as a legal, grey-market alternative to MDMA, and is typically commercially distributed by online research chemical vendors. It is highly advised to use harm reduction practices if using this substance.
Where to order 6-APB Online
The synthesis of 6-APB was first reported by a team led by the medicinal chemist and psychedelic researcher David E. Nichols at Purdue University. They were examining the role of the MDA dioxle ring structure in interacting with serotonergic neurons. It was also partly an effort to find an alternative to MDMA, which was gaining recognition as a potentially useful adjunct in psychotherapy, but was also being linked to neurotoxic effects.
Human usage was not documented until 2010, when it emerged for sale on the research chemical market. It was particularly prominent in the UK “legal highs” market, where it was sold under the name “Benzofury“.
Buy 6-APB Drug Online
On June 10, 2013 6-APB and a number of analogues were classified as Temporary Class Drugs in the UK following an ACMD recommendation. On November 28, 2013 the ACMD recommended that 6-APB and related benzofurans should become Class B, Schedule 1 substances. On March 5, 2014 the UK Home Office announced that 6-APB would be made a class B drug on 10 June 2014 alongside every other benzofuran entactogen and many structurally related drugs.